Elan has accumulated an impressive portfolio of marketed oncology products and a growing pipeline of R&D projects. This franchise includes:
* Myocet/D99, a novel liposomal doxorubicin formulation for the treatment of metastatic breast cancer which has recently been launched in the EU, is under registration in Canada and is in Phase II trials in the US. Phase III plans are being finalized. * ELL-12, a novel ether lipid which we expect to enter into Phase II trials for renal cell carcinoma, metastatic melanoma, non-small cell lung cancer and myelodysplastic syndrome. * BRT-216, a novel taxane which we expect to enter into Phase I trials for solid tumors. * Elan is developing a range of oncology products licensed for Europe from Ligand Pharmaceuticals. These products are Targretin(TM) capsules (marketed) Targretin(TM) gel (in registration) and Onzar/Ontak(TM) (in registration), all initially developed for the treatment of cutaneous T-cell lyphoma, and Panretin(TM) gel, approved for the treatment of Kaposi's sarcoma. * Depocyte(TM) (cytarabine liposomal injection) licensed for Europe from SkyePharma, which is approved for the treatment of lymphomatous meningitis.